Pricing Log in Create free account

Lineage Cell Therapeutics, Inc. (LCTX) vs ARS Pharmaceuticals, Inc. (SPRY)

Lineage Cell Therapeutics, Inc. and ARS Pharmaceuticals, Inc. are both Biotechnology companies. Lineage Cell Therapeutics, Inc. and ARS Pharmaceuticals, Inc. are of similar size ($280.5M and $258.0M). Lineage Cell Therapeutics, Inc. grew revenue faster over the last twelve months: 19.9% against −14.5%. ARS Pharmaceuticals, Inc. has the higher net margin (0.00% vs −246.6%) and the higher return on invested capital (0.00% vs −186.8%). Across the 16 metrics below, ARS Pharmaceuticals, Inc. leads on 10 and Lineage Cell Therapeutics, Inc. on 6.

Valuation

Metric LCTX SPRY Biotechnology median
P/E n/m n/m 10.60
P/S 19.45 2.28 9.40
P/B 4.26 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 15.57 2.55 9.02
Earnings yield (14.10%) (72.40%) (32.88%)
Free cash flow yield (9.58%) (71.47%) (23.13%)

Profitability

Metric LCTX SPRY Biotechnology median
Gross margin 99.46% 0.00% 68.51%
Operating margin (205.23%) (161.50%) 0.00%
Net margin (246.58%) 0.00% 0.00%
Free cash flow margin (186.43%) (149.89%) 0.00%
Return on equity (60.35%) 0.00% (51.96%)
Return on assets (32.75%) 0.00% (46.06%)
Return on invested capital (186.79%) 0.00% 0.00%

Growth

Metric LCTX SPRY Biotechnology median
Revenue growth (TTM) 19.87% (14.45%) 6.76%
EPS growth (last fiscal year) (211.11%) (2,275.00%) 29.88%
Revenue growth, 5-year CAGR 51.46% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LCTX SPRY Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.61 3.25 4.97
Net debt to EBITDA 2.64 0.42 1.01

Dividend

Metric LCTX SPRY Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LCTX SPRY Biotechnology median
Market cap 257.97m 280.47m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack